Paydaş, SemraLaçin, ŞahinDoğan, MutluBarışta, İbrahimYıldız, BirolSeydaoğlu, GülşahCivriz, SinemKaplan, Muhammed AliYağcı, MünciGürkan, EmelErçolak, Vehbi2022-06-222022-06-222021Paydaş, S., Laçin, Ş., Doğan, M., Barışta, İ., Yıldız, B., Seydaoğlu, G. ve diğerleri. (2021). IPS-3 Validation in 1012 cases with classical hodgkin lymphoma. Leukemia Research, (102). 1-5.0145-21261873-5835https://www.sciencedirect.com/science/article/pii/S0145212621000205?via%3Dihubhttps://hdl.handle.net/11468/10059WOS:000628753200001PMID: 33556744The aim of this study is to validate the IPS-3 scoring system as a prognostic indicator in 1012 patients with advanced stage classical Hodgkin Lymphoma (cHL) treated by doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD). According to the IPS-3 scoring system only 3.5 % had high risk and 50.8 % had low risk disease disease and 45.8 % of the cases had intermediate risk disease. Each factors of IPS-7 and IPS-3 scoring systems (age, sex, stage hemoglobin, albumin, lymphocyte count and white cell count) were found to be significant for overall survival (OS) and progression free survival (PFS) according to univariate analyses. Two different multivariate Cox analyses were performed for OS and PFS including the IPS-3/ IPS-7 scoring system parameters. Among 7 risk factors of IPS scoring system, gender and albumin were not found as independent risk factors for both OS and PFS according to cox regression model. But all parameters such as age, stage and hemoglobin those included in IPS-3, were found to be independent significant risk factors for both models obtained for OS and PFS. The results of the study shows that the IPS-3 scoring system can be used as a prognostic indicator in ABVD treated patients in every day practice which is more easily calculate according to the IPS-7.eninfo:eu-repo/semantics/closedAccessIPS-3Hodgkin lymphomaValidationSurvivalArticle10215WOS:0006287532000012-s2.0-851004228623355674410.1016/j.leukres.2021.106519Q3Q3